NERV
Minerva Neurosciences, Inc.
Price Chart
Latest Quote
$4.27
+0.06 (+1.43%)
Current Price
| Previous Close | $4.21 |
| Open | $4.13 |
| Day High | $4.41 |
| Day Low | $4.01 |
| Volume | 169,227 |
Stock Information
| Shares Outstanding | 46.59M |
| Total Debt | $60.00M |
| Cash Equivalents | $78.06M |
| Net Income | $-415.07M |
| Sector | Healthcare |
| Industry | Biotechnology |
| Market Cap | $198.93M |
| EPS (TTM) | $-37.03 |
| Exchange | NCM |
đ Comprehensive Analysis
Company Data
| Enterprise Value | $185.83M |
| Income | $-415.07M |
| Book/sh | $-5.79 |
| Cash/sh | $1.68 |
| Employees | 7 |
Financial Ratios
| Quick Ratio | 17.42 |
| Current Ratio | 17.65 |
Returns & Margins
| ROA | -27.47% |
Ownership
| Insider Ownership | 3.34% |
| Institutional Ownership | 97.40% |
| Insider & Institutional transactions data not available | |
Valuation Ratios
| Forward P/E | -8.90 |
| P/B | -0.74 |
Analyst Data
| Recommendation | none |
| Target Price | $9.50 |
Technical Indicators
| SMA20 | $4.62 |
| SMA50 | $4.87 |
| SMA200 | $4.90 |
| RSI | 48.52 |
| ATR | 0.4631 |
| Shares Float | 30.87M |
| Short Float | 4.28% |
| Short Ratio | 5.59 |
| Volatility | -0.18 |
| Rel Volume | 0.43 |
Performance History
| Week | -9.53% |
| Month | -2.29% |
| Quarter | -32.11% |
| 6 Months | -0.93% |
| YTD | +8.93% |
| Year | +102.85% |
| 3 Years | -67.28% |
| 5 Years | -76.28% |
| 10 Years | -94.93% |
Stock Score:
â Premium
Based on debt, profitability, growth, and cash flow metrics
â Premium Feature
Sign up for free to view detailed scoring breakdown â premium is free during our trial period!
Recent Price History
| Date | Close | Volume |
|---|---|---|
| 2026-07-17 | $4.27 | 169,900 |
| 2026-07-16 | $4.21 | 166,300 |
| 2026-07-15 | $4.32 | 186,900 |
| 2026-07-14 | $4.02 | 170,800 |
| 2026-07-13 | $4.27 | 160,800 |
| 2026-07-10 | $4.72 | 235,000 |
| 2026-07-09 | $4.72 | 195,400 |
| 2026-07-08 | $4.62 | 166,200 |
| 2026-07-07 | $4.77 | 188,400 |
| 2026-07-06 | $4.92 | 239,600 |
| 2026-07-02 | $5.10 | 286,900 |
| 2026-07-01 | $5.15 | 124,200 |
| 2026-06-30 | $5.55 | 221,300 |
| 2026-06-29 | $5.43 | 379,600 |
| 2026-06-26 | $4.37 | 3,867,700 |
| 2026-06-25 | $4.11 | 211,300 |
| 2026-06-24 | $4.33 | 131,100 |
| 2026-06-23 | $4.35 | 126,400 |
| 2026-06-22 | $4.66 | 164,900 |
| 2026-06-18 | $4.47 | 575,000 |
About Minerva Neurosciences, Inc.
Minerva Neurosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of product candidates for the treatment of central nervous system diseases. Its lead product candidate is roluperidone, which is in Phase 3 confirmatory trial for the treatment of negative symptoms in patients with schizophrenia. Minerva Neurosciences, Inc. was incorporated in 2007 and is based in Burlington, Massachusetts.
đ° Latest News
All You Need to Know About Minerva Neurosciences (NERV) Rating Upgrade to Buy
Zacks âĸ 2026-05-20T16:00:03Z
Minerva Neurosciences (NERV) Loses 37.5% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
Zacks âĸ 2026-05-20T13:35:03Z
Minerva Neurosciences Touts Roluperidone Data, FDA-Aligned Trial Plan for Schizophrenia Symptoms
MarketBeat âĸ 2026-03-21T05:02:39Z
Minerva Neurosciences: Q4 Earnings Snapshot
Associated Press Finance âĸ 2026-03-11T11:20:05ZInstitutions profited after Minerva Neurosciences, Inc.'s (NASDAQ:NERV) market cap rose US$27m last week but individual investors profited the most
Simply Wall St. âĸ 2026-02-16T10:45:24Z
Minerva Neurosciences Spotlights Roluperidone, Lays Out Confirmatory Phase 3 Timeline for Schizophrenia
MarketBeat âĸ 2026-02-04T07:07:50Z
Minerva Neurosciences: Q3 Earnings Snapshot
Associated Press Finance âĸ 2025-11-05T12:40:50ZTop Midday Gainers
MT Newswires âĸ 2025-10-21T17:36:17ZBC-Most Active Stocks
Associated Press Finance âĸ 2025-10-21T14:30:28ZMinerva Neurosciences: Q2 Earnings Snapshot
Associated Press Finance âĸ 2025-08-14T20:43:59Z
Period:
Loading...
Income Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Revenue | ||||
| Total Revenue | $0 | $0 | $0 | $0 |
| Operating Revenue | $0 | $0 | $0 | $0 |
| Expenses | ||||
| Interest Expense | $0 | $4,562,223 | $8,282,947 | $7,406,555 |
| Total Expenses | $15,102,970 | $21,848,386 | $23,119,576 | $25,231,326 |
| Other Income Expense | $-275,217,558 | $27,849,474 | $1,397,170 | $529,205 |
| Other Non Operating Income Expenses | $-321,499,041 | $26,579,046 | - | - |
| Net Non Operating Interest Income Expense | $-3,102,649 | $-4,562,223 | $-8,282,947 | $-7,406,555 |
| Total Other Finance Cost | $3,102,649 | - | - | - |
| Interest Expense Non Operating | $0 | $4,562,223 | $8,282,947 | $7,406,555 |
| Operating Expense | $15,102,970 | $21,848,386 | $23,119,576 | $25,231,326 |
| General And Administrative Expense | $9,343,497 | $9,949,791 | $10,414,323 | $10,582,239 |
| Income & Earnings | ||||
| Net Income From Continuing Operation Net Minority Interest | $-293,423,177 | $1,438,865 | $-30,005,353 | $-32,108,676 |
| Net Interest Income | $-3,102,649 | $-4,562,223 | $-8,282,947 | $-7,406,555 |
| Normalized Income | $-339,704,660 | $168,437 | $-31,402,523 | $-32,637,881 |
| Net Income From Continuing And Discontinued Operation | $-293,423,177 | $1,438,865 | $-30,005,353 | $-32,108,676 |
| Total Operating Income As Reported | $-15,102,970 | $-21,848,386 | $-23,119,576 | $-25,231,326 |
| Net Income Common Stockholders | $-293,423,177 | $1,438,865 | $-30,005,353 | $-32,108,676 |
| Net Income | $-293,423,177 | $1,438,865 | $-30,005,353 | $-32,108,676 |
| Net Income Including Noncontrolling Interests | $-293,423,177 | $1,438,865 | $-30,005,353 | $-32,108,676 |
| Net Income Continuous Operations | $-293,423,177 | $1,438,865 | $-30,005,353 | $-32,108,676 |
| Pretax Income | $-293,423,177 | $1,438,865 | $-30,005,353 | $-32,108,676 |
| Operating Income | $-15,102,970 | $-21,848,386 | $-23,119,576 | $-25,231,326 |
| Interest Income | - | - | $1,437,405 | $556,946 |
| Interest Income Non Operating | - | - | $1,437,405 | $556,946 |
| Per Share | ||||
| Diluted EPS | $-34.67 | $0.19 | $-4.61 | $-6.01 |
| Basic EPS | $-34.67 | $0.19 | $-4.61 | $-6.01 |
| Other | ||||
| Tax Effect Of Unusual Items | $0 | $0 | $0 | $0 |
| Tax Rate For Calcs | $0 | $0 | $0 | $0 |
| Normalized EBITDA (Bullshit earnings) | $-339,699,218 | $4,753,129 | $-23,088,594 | $-25,222,813 |
| Total Unusual Items | $46,281,483 | $1,270,428 | $1,397,170 | $529,205 |
| Total Unusual Items Excluding Goodwill | $46,281,483 | $1,270,428 | $1,397,170 | $529,205 |
| Reconciled Depreciation | $5,442 | $22,469 | $30,982 | $8,513 |
| EBITDA (Bullshit earnings) | $-293,417,735 | $6,023,557 | $-21,691,424 | $-24,693,608 |
| EBIT | $-293,423,177 | $6,001,088 | $-21,722,406 | $-24,702,121 |
| Diluted Average Shares | $8,464,000 | $7,573,763 | $6,506,372 | $5,340,194 |
| Basic Average Shares | $8,464,000 | $7,568,981 | $6,506,372 | $5,340,194 |
| Diluted NI Availto Com Stockholders | $-293,423,177 | $1,438,865 | $-30,005,353 | $-32,108,676 |
| Gain On Sale Of Security | $46,281,483 | $1,270,428 | $1,397,170 | $529,205 |
| Research And Development | $5,759,473 | $11,898,595 | $12,705,253 | $14,649,087 |
| Selling General And Administration | $9,343,497 | $9,949,791 | $10,414,323 | $10,582,239 |
| Other Gand A | $9,343,497 | $9,949,791 | $10,414,323 | $10,582,239 |
| Tax Provision | - | - | - | $0 |
Fetched: 2026-07-10
Balance Sheet (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Assets | ||||
| Net Tangible Assets | $-155,617,481 | $-40,562,499 | $-43,343,916 | $-34,936,185 |
| Total Assets | $97,968,888 | $37,143,744 | $56,899,750 | $55,087,233 |
| Total Non Current Assets | $14,869,399 | $14,874,841 | $14,897,310 | $14,928,292 |
| Goodwill And Other Intangible Assets | $14,869,399 | $14,869,399 | $14,886,426 | $14,911,966 |
| Current Assets | $83,099,489 | $22,268,903 | $42,002,440 | $40,158,941 |
| Other Current Assets | $697,676 | $806,895 | $989,865 | $3,965,335 |
| Restricted Cash | $100,000 | $100,000 | $100,000 | $100,000 |
| Cash Cash Equivalents And Short Term Investments | $82,301,813 | $21,362,008 | $40,912,575 | $36,093,606 |
| Cash And Cash Equivalents | $82,301,813 | $21,362,008 | $40,912,575 | $36,093,606 |
| Other Intangible Assets | - | - | $17,027 | $42,567 |
| Prepaid Assets | - | - | - | - |
| Debt | ||||
| Total Debt | - | - | - | - |
| Liabilities | ||||
| Total Liabilities Net Minority Interest | $238,716,970 | $62,836,844 | $85,357,240 | $75,111,452 |
| Total Non Current Liabilities Net Minority Interest | $236,426,497 | $60,000,000 | $82,016,823 | $73,733,876 |
| Other Non Current Liabilities | $60,000,000 | $60,000,000 | $82,016,823 | $73,733,876 |
| Derivative Product Liabilities | $171,464,575 | $0 | - | - |
| Current Liabilities | $2,290,473 | $2,836,844 | $3,340,417 | $1,377,576 |
| Payables And Accrued Expenses | $2,290,473 | $2,473,663 | $2,749,648 | $1,362,744 |
| Payables | $639,707 | $1,607,844 | $1,805,320 | $969,667 |
| Accounts Payable | $639,707 | $1,607,844 | $1,805,320 | $969,667 |
| Non Current Deferred Liabilities | - | - | - | - |
| Non Current Deferred Taxes Liabilities | - | - | - | - |
| Equity | ||||
| Common Stock Equity | $-140,748,082 | $-25,693,100 | $-28,457,490 | $-20,024,219 |
| Total Equity Gross Minority Interest | $-140,748,082 | $-25,693,100 | $-28,457,490 | $-20,024,219 |
| Stockholders Equity | $-140,748,082 | $-25,693,100 | $-28,457,490 | $-20,024,219 |
| Retained Earnings | $-688,799,740 | $-395,376,563 | $-396,815,428 | $-366,810,075 |
| Preferred Securities Outside Stock Equity | $4,961,922 | $0 | - | - |
| Other | ||||
| Ordinary Shares Number | $43,274,398 | $6,993,406 | $6,993,406 | $5,340,193 |
| Share Issued | $43,274,398 | $6,993,406 | $6,993,406 | $5,340,193 |
| Tangible Book Value | $-155,617,481 | $-40,562,499 | $-43,343,916 | $-34,936,185 |
| Invested Capital | $-140,748,082 | $-25,693,100 | $-28,457,490 | $-20,024,219 |
| Working Capital | $80,809,016 | $19,432,059 | $38,662,023 | $38,781,365 |
| Total Capitalization | $-140,748,082 | $-25,693,100 | $-28,457,490 | $-20,024,219 |
| Additional Paid In Capital | $548,047,331 | $369,682,764 | $368,357,239 | $346,785,322 |
| Capital Stock | $4,327 | $699 | $699 | $534 |
| Common Stock | $4,327 | $699 | $699 | $534 |
| Pensionand Other Post Retirement Benefit Plans Current | $0 | $363,181 | $590,769 | $14,832 |
| Current Accrued Expenses | $1,650,766 | $865,819 | $944,328 | $393,077 |
| Goodwill | $14,869,399 | $14,869,399 | $14,869,399 | $14,869,399 |
| Net PPE | $0 | $5,442 | $10,884 | $16,326 |
| Preferred Stock | - | $0 | $0 | $0 |
| Gross PPE | - | - | - | $16,326 |
| Other Properties | - | - | - | $16,326 |
| Capital Lease Obligations | - | - | - | - |
| Current Capital Lease Obligation | - | - | - | - |
| Buildings And Improvements | - | - | - | - |
| Properties | - | - | - | - |
Fetched: 2026-07-10
Cash Flow Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Free Cash Flow | ||||
| Free Cash Flow | $-13,510,936 | $-19,550,567 | $-14,784,732 | $-24,661,469 |
| Operating Activities | ||||
| Operating Cash Flow | $-13,510,936 | $-19,550,567 | $-14,784,732 | $-24,645,143 |
| Cash Flow From Continuing Operating Activities | $-13,510,936 | $-19,550,567 | $-14,784,732 | $-24,645,143 |
| Operating Gains Losses | $279,211,774 | - | - | - |
| Investing Activities | ||||
| Investing Cash Flow | $0 | $0 | $0 | $-16,326 |
| Cash Flow From Continuing Investing Activities | - | - | $0 | $-16,326 |
| Capital Expenditure | - | - | - | $-16,326 |
| Financing Activities | ||||
| Issuance Of Capital Stock | $80,000,000 | $0 | $19,999,994 | $0 |
| Financing Cash Flow | $74,450,741 | $0 | $19,603,701 | $-5 |
| Cash Flow From Continuing Financing Activities | $74,450,741 | $0 | $19,603,701 | $-5 |
| Net Other Financing Charges | $-5,549,259 | - | $-396,293 | $-5 |
| Net Preferred Stock Issuance | $80,000,000 | $0 | - | - |
| Preferred Stock Issuance | $80,000,000 | $0 | - | - |
| Net Common Stock Issuance | - | $0 | $19,999,994 | $0 |
| Common Stock Issuance | - | $0 | $19,999,994 | $0 |
| Other | ||||
| End Cash Position | $82,401,813 | $21,462,008 | $41,012,575 | $36,193,606 |
| Beginning Cash Position | $21,462,008 | $41,012,575 | $36,193,606 | $60,855,080 |
| Changes In Cash | $60,939,805 | $-19,550,567 | $4,818,969 | $-24,661,474 |
| Change In Working Capital | $-632,347 | $-320,603 | $4,938,311 | $-4,060,354 |
| Change In Payables And Accrued Expense | $-741,566 | $-503,573 | $1,962,841 | $-1,441,378 |
| Change In Accrued Expense | $317,446 | $-306,097 | $1,127,188 | $-557,830 |
| Change In Payable | $-1,059,012 | $-197,476 | $835,653 | $-883,548 |
| Change In Account Payable | $-1,059,012 | $-197,476 | $835,653 | $-883,548 |
| Change In Prepaid Assets | $109,219 | $182,970 | $-141,748 | $498,242 |
| Stock Based Compensation | $1,327,372 | $1,325,525 | $1,968,381 | $4,108,819 |
| Depreciation Amortization Depletion | $5,442 | $22,469 | $30,982 | $8,513 |
| Depreciation And Amortization | $5,442 | $22,469 | $30,982 | $8,513 |
| Amortization Cash Flow | $0 | $17,027 | $25,540 | $8,513 |
| Amortization Of Intangibles | $0 | $17,027 | $25,540 | $8,513 |
| Depreciation | $5,442 | $5,442 | $5,442 | $0 |
| Gain Loss On Investment Securities | $279,211,774 | - | - | - |
| Net Income From Continuing Operations | $-293,423,177 | $1,438,865 | $-30,005,353 | $-32,108,676 |
| Change In Other Current Assets | - | $0 | $3,117,218 | $-3,117,218 |
| Other Non Cash Items | - | $-22,016,823 | $8,282,947 | $7,406,555 |
| Net PPE Purchase And Sale | - | - | $0 | $-16,326 |
| Purchase Of PPE | - | - | $0 | $-16,326 |
| Change In Other Working Capital | - | - | - | $-3,117,218 |
| Change In Other Current Liabilities | - | - | - | $0 |
| Asset Impairment Charge | - | - | - | $0 |
| Interest Paid Supplemental Data | - | - | - | - |
| Proceeds From Stock Option Exercised | - | - | - | - |
| Net Investment Purchase And Sale | - | - | - | - |
| Sale Of Investment | - | - | - | - |
| Purchase Of Investment | - | - | - | - |
| Amortization Of Securities | - | - | - | - |
| Deferred Tax | - | - | - | - |
| Deferred Income Tax | - | - | - | - |
Fetched: 2026-07-10